Evidence map›Paper›PMID 41047708›Full record

Trial reportFuture oncology (London, England)2025

EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial).

Maeve A Hennessy, Constantine Gatsonis, Heather Jacene, Roisin M Connolly, Brian L Burnette, Erica M Stringer-Reasor, Justin Romanoff, Alexander Taurone, Ciara C O'Sullivan, Huong T Le-Petross and 7 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05710328 (Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05710328 phase2active not recruitingnot on this map

Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT Trial

TypeinterventionalSponsorECOG-ACRIN Cancer Research GroupRan2023 to 2029Enrolled235ConditionsAnatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast CarcinomaArmsChemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Surgical Procedure
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A compositeBreast (Edinburgh, Scotland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Maeve A HennessyCancer Research @UCC, College of Medicine & Health, University College Cork, Cork, Ireland.
Constantine GatsonisBrown University School of Public Health - Center for Biostatistics and Health Data Science, Providence, RI, USA.
Heather JaceneDana-Farber/Brigham Cancer Center, Boston, MA, USA.
Roisin M ConnollyCancer Research @UCC, College of Medicine & Health, University College Cork, Cork, Ireland.
Brian L BurnetteSaint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, USA.
Erica M Stringer-ReasorUniversity of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, Birmingham, AL, USA.
Justin RomanoffBrown University School of Public Health - Center for Biostatistics and Health Data Science, Providence, RI, USA.
Alexander TauroneBrown University School of Public Health - Center for Biostatistics and Health Data Science, Providence, RI, USA.
Ciara C O'SullivanMayo Clinic, Rochester, MN, USA.
Huong T Le-PetrossUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vered StearnsJohn Hopkins University/Sidney Kimmel Cancer Center, Baltimore, MD, USA.
Amy M FowlerUniversity of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Shou-Ching TangLouisiana State University Health Sciences Center, New Orleans, LA, USA.
Karla A SepulvedaBaylor College of Medicine, Houston, TX, USA.
Angela M DeMicheleUniversity of Pennsylvania/Abramson Cancer Center, Philadelphia, PA, USA.
David A MankoffUniversity of Pennsylvania/Abramson Cancer Center, Philadelphia, PA, USA.
Antonio C WolffJohn Hopkins University/Sidney Kimmel Cancer Center, Baltimore, MD, USA.

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
Statistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2M
Cancer Research of Wisconsin and Northern Michigan (CROWN) ConsortiumUG1CA239769 · NCI · ST. VINCENT HOSPITAL · PI Anthony J Jaslowski · 2019 to 2026
$15.8M
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1UG1CA233329 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KELLY K HUNT, CHELSEA Camille PINNIX · 2019 to 2026
$11.1M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 (funded extension)UG1CA232760 · NCI · MAYO CLINIC ROCHESTER · PI Judy Caroline Boughey, Aaron Scott Mansfield · 2019 to 2026
$8.5M
National Clinical Trials Network Research at the University of WisconsinUG1CA233277 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Lisa M Barroilhet, Andrew M. Baschnagel · 2019 to 2026
$4.9M
NCTN LAPS at Johns HopkinsUG1CA233196 · NCI · JOHNS HOPKINS UNIVERSITY · PI DEBORAH K ARMSTRONG, Julie Renee Brahmer · 2019 to 2026
$4.6M
NCTN Deep South Research ConsortiumUG1CA233330 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Charles A. Leath, Andrew M McDonald · 2019 to 2026
$3.7M
NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180868NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA232760NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233196NCI NIH HHS UG1 CA233277NCI NIH HHS UG1 CA233329NCI NIH HHS UG1 CA233330NCI NIH HHS UG1 CA239769
6 · The paper itself

Abstract

CLINICAL

trial registrationNCT05710328.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesPositron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsFemaleFluorodeoxyglucose F18HumansMiddle AgedNeoadjuvant TherapyRadiopharmaceuticalsTreatment OutcomeERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFluorodeoxyglucose F18Radiopharmaceuticalsclinical trialsFDG-PET/CTHER2-positive breast cancerimaging biomarkersneoadjuvantprecision oncology

Identifiers

PMID41047708
PMCPMC12582116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.